Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Will we ever see the approval of a Staphylococcus aureus vaccine?

Patti JM.

Expert Rev Anti Infect Ther. 2011 Oct;9(10):845-6. doi: 10.1586/eri.11.99. No abstract available.

PMID:
21973294
2.

Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers.

Pentikis HS, Matson M, Atiee G, Boehlecke B, Hutchins JT, Patti JM, Henson GW, Morris A.

Antimicrob Agents Chemother. 2011 Jun;55(6):2847-54. doi: 10.1128/AAC.01446-10. Epub 2011 Mar 28.

3.

INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.

Vernachio JH, Bleiman B, Bryant KD, Chamberlain S, Hunley D, Hutchins J, Ames B, Gorovits E, Ganguly B, Hall A, Kolykhalov A, Liu Y, Muhammad J, Raja N, Walters CR, Wang J, Williams K, Patti JM, Henson G, Madela K, Aljarah M, Gilles A, McGuigan C.

Antimicrob Agents Chemother. 2011 May;55(5):1843-51. doi: 10.1128/AAC.01335-10. Epub 2011 Feb 28.

4.

Antibody response to the extracellular adherence protein (Eap) of Staphylococcus aureus in healthy and infected individuals.

Joost I, Jacob S, Utermöhlen O, Schubert U, Patti JM, Ong MF, Gross J, Justinger C, Renno JH, Preissner KT, Bischoff M, Herrmann M.

FEMS Immunol Med Microbiol. 2011 Jun;62(1):23-31. doi: 10.1111/j.1574-695X.2011.00783.x. Epub 2011 Feb 14.

5.

Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus.

McGuigan C, Madela K, Aljarah M, Gilles A, Brancale A, Zonta N, Chamberlain S, Vernachio J, Hutchins J, Hall A, Ames B, Gorovits E, Ganguly B, Kolykhalov A, Wang J, Muhammad J, Patti JM, Henson G.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4850-4. doi: 10.1016/j.bmcl.2010.06.094. Epub 2010 Jun 20.

PMID:
20637609
6.

Monoclonal antibodies specific for Candida albicans Als3 that immunolabel fungal cells in vitro and in vivo and block adhesion to host surfaces.

Coleman DA, Oh SH, Zhao X, Zhao H, Hutchins JT, Vernachio JH, Patti JM, Hoyer LL.

J Microbiol Methods. 2009 Jul;78(1):71-8. doi: 10.1016/j.mimet.2009.05.002. Epub 2009 May 7.

7.

Monoclonal antibodies recognizing the Enterococcus faecalis collagen-binding MSCRAMM Ace: conditional expression and binding analysis.

Hall AE, Gorovits EL, Syribeys PJ, Domanski PJ, Ames BR, Chang CY, Vernachio JH, Patti JM, Hutchins JT.

Microb Pathog. 2007 Aug-Sep;43(2-3):55-66. Epub 2007 Apr 19.

PMID:
17521860
8.

A panel of monoclonal antibodies recognizing the Staphylococcus epidermidis fibrinogen-binding MSCRAMM SdrG.

Hall AE, Patel PR, Domanski PJ, Prater BD, Gorovits EL, Syribeys PJ, Vernachio JH, Patti JM, Hutchins JT.

Hybridoma (Larchmt). 2007 Feb;26(1):28-34.

PMID:
17316083
9.

Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis.

Hetherington S, Texter M, Wenzel E, Patti JM, Reynolds L, Shamp T, Swan S.

Antimicrob Agents Chemother. 2006 Oct;50(10):3499-500.

10.

Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia.

Weems JJ Jr, Steinberg JP, Filler S, Baddley JW, Corey GR, Sampathkumar P, Winston L, John JF, Kubin CJ, Talwani R, Moore T, Patti JM, Hetherington S, Texter M, Wenzel E, Kelley VA, Fowler VG Jr.

Antimicrob Agents Chemother. 2006 Aug;50(8):2751-5.

11.

Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo.

Vernachio JH, Bayer AS, Ames B, Bryant D, Prater BD, Syribeys PJ, Gorovits EL, Patti JM.

Antimicrob Agents Chemother. 2006 Feb;50(2):511-8.

12.

Vaccines and immunotherapy for staphylococcal infections.

Patti JM.

Int J Artif Organs. 2005 Nov;28(11):1157-62. Review.

PMID:
16353122
13.

Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.

Domanski PJ, Patel PR, Bayer AS, Zhang L, Hall AE, Syribeys PJ, Gorovits EL, Bryant D, Vernachio JH, Hutchins JT, Patti JM.

Infect Immun. 2005 Aug;73(8):5229-32.

14.

Role of Staphylococcus aureus global regulators sae and sigmaB in virulence gene expression during device-related infection.

Goerke C, Fluckiger U, Steinhuber A, Bisanzio V, Ulrich M, Bischoff M, Patti JM, Wolz C.

Infect Immun. 2005 Jun;73(6):3415-21.

15.

Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers.

Reilley S, Wenzel E, Reynolds L, Bennett B, Patti JM, Hetherington S.

Antimicrob Agents Chemother. 2005 Mar;49(3):959-62.

16.

MSCRAMM--targeted vaccines and immunotherapy for staphylococcal infection.

Rivas JM, Speziale P, Patti JM, Höök M.

Curr Opin Drug Discov Devel. 2004 Mar;7(2):223-7. Review.

PMID:
15603256
17.

A humanized monoclonal antibody targeting Staphylococcus aureus.

Patti JM.

Vaccine. 2004 Dec 6;22 Suppl 1:S39-43. Review.

PMID:
15576200
18.

SdrX, a serine-aspartate repeat protein expressed by Staphylococcus capitis with collagen VI binding activity.

Liu Y, Ames B, Gorovits E, Prater BD, Syribeys P, Vernachio JH, Patti JM.

Infect Immun. 2004 Nov;72(11):6237-44.

19.

Immunotherapeutics for nosocomial infections.

Patti JM.

Expert Opin Investig Drugs. 2004 Jun;13(6):673-9. Review.

PMID:
15174953
20.

Expression of staphylococcal clumping factor A impedes macrophage phagocytosis.

Palmqvist N, Patti JM, Tarkowski A, Josefsson E.

Microbes Infect. 2004 Feb;6(2):188-95.

PMID:
14998517
21.

Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A.

Hall AE, Domanski PJ, Patel PR, Vernachio JH, Syribeys PJ, Gorovits EL, Johnson MA, Ross JM, Hutchins JT, Patti JM.

Infect Immun. 2003 Dec;71(12):6864-70.

22.

Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis.

Vernachio J, Bayer AS, Le T, Chai YL, Prater B, Schneider A, Ames B, Syribeys P, Robbins J, Patti JM.

Antimicrob Agents Chemother. 2003 Nov;47(11):3400-6.

23.

Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant.

Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T.

J Infect Dis. 2001 Dec 15;184(12):1572-80. Epub 2001 Dec 3.

PMID:
11740733
24.

Staphylococcal fibronectin binding protein interacts with heat shock protein 60 and integrins: role in internalization by epithelial cells.

Dziewanowska K, Carson AR, Patti JM, Deobald CF, Bayles KW, Bohach GA.

Infect Immun. 2000 Nov;68(11):6321-8.

25.

The collagen-binding adhesin is a virulence factor in Staphylococcus aureus keratitis.

Rhem MN, Lech EM, Patti JM, McDevitt D, Höök M, Jones DB, Wilhelmus KR.

Infect Immun. 2000 Jun;68(6):3776-9.

26.

Fibronectin binding protein and host cell tyrosine kinase are required for internalization of Staphylococcus aureus by epithelial cells.

Dziewanowska K, Patti JM, Deobald CF, Bayles KW, Trumble WR, Bohach GA.

Infect Immun. 1999 Sep;67(9):4673-8.

27.

Crystallization and preliminary X-ray analysis of B-domain fragments of a Staphylococcus aureus collagen-binding protein.

Deivanayagam CC, Rich RL, Danthuluri S, Owens RT, Patti JM, Höök M, DeLucas LJ, Narayana SV.

Acta Crystallogr D Biol Crystallogr. 1999 Feb;55(Pt 2):525-7.

PMID:
10089366
28.

Inhibition of Staphylococcus aureus adherence to collagen under dynamic conditions.

Mohamed N, Teeters MA, Patti JM, Höök M, Ross JM.

Infect Immun. 1999 Feb;67(2):589-94.

29.

Domain structure of the Staphylococcus aureus collagen adhesin.

Rich RL, Demeler B, Ashby K, Deivanayagam CC, Petrich JW, Patti JM, Narayana SV, Höök M.

Biochemistry. 1998 Nov 3;37(44):15423-33.

PMID:
9799504
30.

Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death.

Nilsson IM, Patti JM, Bremell T, Höök M, Tarkowski A.

J Clin Invest. 1998 Jun 15;101(12):2640-9.

31.

Structure of the collagen-binding domain from a Staphylococcus aureus adhesin.

Symersky J, Patti JM, Carson M, House-Pompeo K, Teale M, Moore D, Jin L, Schneider A, DeLucas LJ, Höök M, Narayana SV.

Nat Struct Biol. 1997 Oct;4(10):833-8.

PMID:
9334749
32.

The Staphylococcus aureus collagen adhesin-encoding gene (cna) is within a discrete genetic element.

Gillaspy AF, Patti JM, Pratt FL Jr, Iandolo JJ, Smeltzer MS.

Gene. 1997 Sep 1;196(1-2):239-48. Erratum in: Gene 1997 Dec 5;203(1):87.

PMID:
9322763
33.

Transcriptional regulation of the Staphylococcus aureus collagen adhesion gene, cna.

Gillaspy AF, Patti JM, Smeltzer MS.

Infect Immun. 1997 Apr;65(4):1536-40.

34.
35.

Role of Staphylococcus aureus surface adhesins in orthopaedic device infections: are results model-dependent?

Darouiche RO, Landon GC, Patti JM, Nguyen LL, Fernau RC, McDevitt D, Greene C, Foster T, Klima M.

J Med Microbiol. 1997 Jan;46(1):75-9.

PMID:
9003749
36.

Analysis of the prtP gene encoding porphypain, a cysteine proteinase of Porphyromonas gingivalis.

Barkocy-Gallagher GA, Han N, Patti JM, Whitlock J, Progulske-Fox A, Lantz MS.

J Bacteriol. 1996 May;178(10):2734-41.

37.
38.

Staphylococcus aureus expresses a major histocompatibility complex class II analog.

Jönsson K, McDevitt D, McGavin MH, Patti JM, Höök M.

J Biol Chem. 1995 Sep 15;270(37):21457-60.

39.

Critical residues in the ligand-binding site of the Staphylococcus aureus collagen-binding adhesin (MSCRAMM).

Patti JM, House-Pompeo K, Boles JO, Garza N, Gurusiddappa S, Höök M.

J Biol Chem. 1995 May 19;270(20):12005-11.

40.

Microbial adhesins recognizing extracellular matrix macromolecules.

Patti JM, Höök M.

Curr Opin Cell Biol. 1994 Oct;6(5):752-8. Review.

PMID:
7833055
41.

Fibronectin receptors from gram-positive bacteria: comparison of active sites.

Joh HJ, House-Pompeo K, Patti JM, Gurusiddappa S, Höök M.

Biochemistry. 1994 May 24;33(20):6086-92.

PMID:
8193122
42.

The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis.

Patti JM, Bremell T, Krajewska-Pietrasik D, Abdelnour A, Tarkowski A, Rydén C, Höök M.

Infect Immun. 1994 Jan;62(1):152-61.

43.

MSCRAMM-mediated adherence of microorganisms to host tissues.

Patti JM, Allen BL, McGavin MJ, Höök M.

Annu Rev Microbiol. 1994;48:585-617. Review.

PMID:
7826020
44.

A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin.

Kapur V, Topouzis S, Majesky MW, Li LL, Hamrick MR, Hamill RJ, Patti JM, Musser JM.

Microb Pathog. 1993 Nov;15(5):327-46.

PMID:
7516997
45.
46.

A collagen receptor on Staphylococcus aureus strains isolated from patients with septic arthritis mediates adhesion to cartilage.

Switalski LM, Patti JM, Butcher W, Gristina AG, Speziale P, Höök M.

Mol Microbiol. 1993 Jan;7(1):99-107.

PMID:
8382334
47.

Molecular characterization and expression of a gene encoding a Staphylococcus aureus collagen adhesin.

Patti JM, Jonsson H, Guss B, Switalski LM, Wiberg K, Lindberg M, Höök M.

J Biol Chem. 1992 Mar 5;267(7):4766-72. Erratum in: J Biol Chem 1994 Apr 15;269(15):11672.

48.

Model for studying bacterial adherence to skin wounds.

Mertz PM, Patti JM, Marcin JJ, Marshall DA.

J Clin Microbiol. 1987 Sep;25(9):1601-4.

Supplemental Content

Loading ...
Support Center